Chardan Capital Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS)

Chardan Capital reaffirmed their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the biopharmaceutical company’s stock. Chardan Capital also issued estimates for Arbutus Biopharma’s FY2025 earnings at ($0.30) EPS.

Several other research firms have also weighed in on ABUS. StockNews.com lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Trading Up 7.0 %

NASDAQ:ABUS opened at $3.50 on Friday. The stock’s 50-day moving average is $3.34 and its 200-day moving average is $3.55. The stock has a market cap of $663.22 million, a P/E ratio of -8.14 and a beta of 1.93. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS) last announced its earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. As a group, equities analysts forecast that Arbutus Biopharma will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Arbutus Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of ABUS. E Fund Management Co. Ltd. bought a new stake in Arbutus Biopharma in the 4th quarter valued at about $34,000. Xponance Inc. purchased a new position in shares of Arbutus Biopharma in the fourth quarter worth about $34,000. Raymond James Financial Inc. bought a new stake in shares of Arbutus Biopharma in the fourth quarter valued at approximately $34,000. Cibc World Markets Corp purchased a new stake in shares of Arbutus Biopharma during the 4th quarter valued at approximately $45,000. Finally, Hsbc Holdings PLC bought a new position in Arbutus Biopharma in the 4th quarter worth approximately $55,000. 43.79% of the stock is owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.